drugset / Trial / NCT03705637

Liposomal Bupivicaine for Skin Graft Donor Sites in Burn Patients

NCT03705637

Phase 0 Terminated 6 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelOther

Summary

Burn injuries are painful to patients and the sources of pain result from many areas including: the injury itself, wound care, and surgery. Inpatients that require surgical skin grafting is often required and the donor site of a skin graft is quite painful for patients. The investigators try to minimize that pain with local anesthetic as well as a combination of pain medications, the donor site pain lasts for days and is what patients often report as being the most painful part of their burn care. There has been the development of a new form of local anesthesia that can last up to 72 hours when injected into tissue. Based on encouraging results in the literature in areas outside of burns, this study aims to evaluate whether administration of this medication at the time of surgery can help improve pain for burn patients in the postoperative period.

Timeline

Start
2019-06-01
Primary completion
2020-03-24
Completion
2020-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 266 mg Other

Indications

No indication recorded.